Caregiver Homes Receives Highest Status of Case Management Accreditation from the National Committee for Quality Assurance (NCQA) Sep 16, 2014 07:30AM

BOSTON, MA (PRWEB) September 16, 2014

Caregiver Homes Network, Inc. has achieved the highest accreditation status of Case Management Accreditation from the National Committee for Quality Assurance (NCQA). The Structured Family Caregiving model of care delivered by Caregiver Homes has received this accreditation, which recognizes service and quality that demonstrates strong performance that meets NCQA's rigorous requirements for case management.

NCQA's Case Management Accreditation is a comprehensive, evidence-based accreditation program dedicated to quality improvement that can be used for case management programs in provider, payer or community-based organizations. The highest accreditation status extends accreditation to an organization for three years.

"Managed Care Organizations consider NCQA accreditation to be the benchmark for evaluating other quality healthcare organizations," said Caregiver Homes CEO Tom Riley. "Caregiver Homes is extremely proud to be the first entity focused on home and community based services (HCBS) to achieve an NCQA Case Management Accreditation."

Margaret E. O'Kane, President, NCQA, said, "Case Management Accreditation moves us closer to measuring quality across population health management initiatives. Not only does it add value to existing quality improvement efforts; it also demonstrates an organization's commitment to the highest degree of improving the quality of their patients' care."

About Caregiver Homes
Caregiver Homes provides a unique, long-term care service model called Structured Family Caregiving (SFC), recognized in Connecticut as Adult Family Living, in Indiana as Structured Family Caregiving, in Ohio as Adult Family Living, in Massachusetts as Adult Foster Care, and RIte @ Home in Rhode Island. The organization, a wholly owned subsidiary of Boston-based Seniorlink, Inc. is dedicated to supporting elders with complex medical conditions and people with disabilities live with dignity and independence in their communities. Caregiver Homes employs highly-qualified professionals and specially-designed communication technology to empower caregivers to provide effective, high-quality care at home and to be paid for their commitment. The program was launched in 2005 and is actively serving more than 2,300 clinically complex consumers in five states.

Seniorlink, Inc. offers expertise in managing care for elders and people with disabilities. In addition to its innovative service model, Structured Family Caregiving (SFC), Seniorlink offers expertise to States and Managed Care Organizations regarding cost-effective, long-term care services.

About NCQA
NCQA is a private, non-profit organization dedicated to improving health care quality. NCQA accredits and certifies a wide range of health care organizations. It also recognizes clinicians and practices in key areas of performance. NCQA is committed to providing health care quality information for consumers, purchasers, health care providers and researchers.

Read the full story at

Trice Medical Receives FDA 510(k) Clearance for mi-eye Sep 16, 2014 07:30AM

King of Prussia, PA (PRWEB) September 16, 2014

King of Prussia, PA, September 16, 2014 – Trice Medical™, a private diagnostics company focused on micro invasive technologies, announced that it received 510(k) regulatory clearance from the United States Food and Drug Administration ("FDA") for its new device, mi-eye™.

mi-eye is designed to provide a more immediate, definitive and less expensive diagnosis, eliminating the false reads of indirect modalities, such as MRIs. mi-eye is a fully disposable, single-use, streamlined visualization device that uses a standard 14-gauge needle with an integrated camera and light source to perform a diagnostic arthroscopy--all while in the physician's office during the initial consultation. A separate LCD tablet, running on Android OS, is attached via a data cable from the mi-eye needle. mi-eye is delivered to customers in sterile packaging and ready for immediate use.

Jeff O'Donnell, Chairman and CEO of Trice Medical, commented, "The FDA clearance of mi-eye is a key milestone in Trice Medical's pursuit of needle based diagnostic and therapeutic technologies. The company will also apply for CE Mark in Europe and approval in many countries outside the U.S."

Trice Medical intends to execute a limited marketing launch beginning in the fourth quarter of 2014. The company is currently building inventory and developing marketing tools and educational programs in preparation for the launch.

In conjunction with the achievement of this regulatory milestone, Trice Medical received the balance of the cash related to its $11.6M Series B financing, which was led by Safeguard Scientifics, Inc. (NYSE:SFE).

About Trice MedicalTM
Trice was founded to fundamentally improve orthopedic diagnostics for the patient, physician, and payer by providing instant, eyes-on, answers. Trice has pioneered fully integrated camera-enabled needle technologies that provide a clinical solution that is optimized for the physician's office. Trice's mission is to provide more immediate and definitive patient care, eliminating the false reads associated with current indirect modalities and significantly reduce the overall cost to the healthcare system. For more information, please visit

Read the full story at

Mylan Commences Phase III Clinical Trials for its Generic Version of Advair Diskus® and Insulin Analog to Lantus® Sep 16, 2014 07:30AM

PITTSBURGH, Sept. 16, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading global pharmaceutical companies, today announced it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's Advair Diskus® and its insulin analog to Sanofi's Lantus®.

In October 2014, Mylan will commence a Phase III clinical trial to evaluate the equivalence of its product to Advair Diskus when administered by inhalation in adult asthma patients.

Two Phase III clinical trials for Mylan's insulin analog program already are underway. In August 2014, the company initiated INSTRIDE 1 and INSTRIDE 2 to compare the efficacy and safety of Mylan's insulin Glargine with that of Lantus® in both Type 1 and Type 2 diabetes mellitus patients.

Mylan CEO Heather Bresch said, "The commencement of Phase III clinical trials for Mylan's generic Advair Diskus® and insulin Glargine programs are important milestones in the progress of two of our strategic growth drivers, demonstrating our strong capabilities in developing complex, difficult-to-manufacture products. We look forward to providing patients with access to high quality, more affordable versions of these medications upon final FDA approval."

Mylan President Rajiv Malik added, "These noteworthy clinical trial developments, combined with the significant strides we have made in advancing our production scale manufacturing, reinforce our continued belief that Mylan will be the first to bring to market an AB-rated, substitutable generic form of Advair Diskus and one of the first to bring to market an interchangeable insulin analog to Lantus. These products, in addition to the hundreds of others in our pipeline, will continue to expand and diversify our portfolio and further differentiate Mylan with its customers."

About Generic Advair Diskus TrialThe clinical trial is a randomized, double-blind, double dummy, parallel group study to determine the local equivalence of multiple doses of Mylan's generic product to Advair Diskus when administered via oral inhalation in adult asthma patients. The primary endpoint of the study is the FEV1 area under the effect curve, which is the volume of air that has been forcibly exhaled in one second, after full inspiration. The study also will examine adverse events and device usability. The study is expected to commence in October 2014 and be completed in April 2015. More information about the trial will be available at

About INSTRIDE 1 and INSTRIDE 2 TrialsINSTRIDE 1 and INSTRIDE 2 are open-label, randomized, multicenter, parallel-group clinical trials comparing the efficacy and safety of Mylan's insulin Glargine with that of Lantus® in Type 1 and Type 2 diabetes mellitus patients, respectively. The purpose of both studies is to test whether Mylan's insulin Glargine once daily is non-inferior to Lantus® once daily when administered in combination with other anti-diabetic drugs. Both studies commenced in August 2014 and are expected to be completed in June 2016.  More information about INSTRIDE 1 and INSTRIDE 2 is available at

This press release includes statements that constitute "forward-looking statements," including with regard to sales of products and the company's strategy, future growth and performance. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the impacts of competition; changes in economic and financial conditions of the company's business; strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; uncertainties and matters beyond the control of management; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside.

Logo -

SOURCE Mylan Inc.

Coty Inc. Declares Annual Dividend of $0.20 Per Share Sep 16, 2014 07:30AM

NEW YORK, Sept. 16, 2014 /PRNewswire/ -- Coty Inc. (NYSE: COTY) will pay an annual dividend of $0.20 per share on its Class A and Class B Common Stock on October 15, 2014 to stockholders of record at the close of business on October 1, 2014.

About Coty Inc.

Coty is a leading global beauty company with net revenues of $4.6 billion for the fiscal year ended June 30, 2014.  Founded in Paris in 1904, Coty is a pure play beauty company with a portfolio of well-known fragrances, color cosmetics and skin & body care products sold in over 130 countries and territories.  Coty's product offerings include such power brands as adidas, Calvin Klein, Chloe, Davidoff, Marc Jacobs, OPI, philosophy, Playboy, Rimmel and Sally Hansen.

For additional information about Coty Inc., please visit

Forward Looking StatementsCertain statements in this release are forward-looking statements. These forward-looking statements reflect Coty Inc.'s (the "Company") current views with respect to its annual dividend and are designated by the word "will" or similar words or phrases.  Actual events may differ from the Company's current views due to risks and uncertainties. More information about potential risks and uncertainties is included under "Risk Factors" and "Management Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2014 and other periodic reports the Company may file with the Securities and Exchange Commission from time to time. The Company assumes no responsibility to update forward-looking statements made herein or otherwise.


SOURCE Coty Inc.

Smart Communications, Inc. ("Smart") Launches Optimized VoIP for Filipino Seafarers Using One Horizon Technology Sep 16, 2014 07:30AM

BAAR, SWITZERLAND -- (Marketwired) -- 09/16/14 -- One Horizon Group, Inc. (NASDAQ: OHGI) ("One Horizon" or the "Company"), which develops and licenses the world's most bandwidth-efficient mobile Voice over Internet Protocol ("VoIP") platform for Smartphones, today announced that Smart Communications, Inc., is launching a pre-paid VoIP Smartphone app using its optimized software platform.

Smart is commencing the rollout of the Smartphone mobile app, branded Link Plus, as a pre-paid Over The Top ("OTT") Android App that will be available to download from the Google Play Store. The target audience for this pay-as-you-go VoIP service is nearly 400,000 Filipino seafarers deployed all over the world. Once Link Plus is installed on the Smartphone, the user's app will receive a new Virtual SIM telephone number from Smart.

Brian Collins, founder and CEO of One Horizon, commented, "The launch of the Smart Virtual SIM Link Plus service using our revolutionary mobile-VoIP technology marks yet another milestone in the delivery of our innovative solutions to operators. Smartphone users all over the world can benefit from the ultra-low bandwidth and high-quality VoIP of the Link Plus app combined with the quality of Smart's core telephone network."

"Download, top-up and you have a true pre-paid Filipino telephone number to call anyone at home at domestic rates. Smart is allowing subscribers to take a little piece of home with them when they go abroad to work. Family and friends can now call their loved ones overseas by calling a local Smart number. This really brings the Filipino seafarer closer to home," added Mr. Collins.

Tina Z. Mariano, Head, Smart Global Access group, said: "At Smart we are always looking for innovation that allows our seafaring subscribers to benefit and utilize our network. The Link Plus app delivers just that, a service that allows them to call to and from home at great local rates. This is a wonderful combination of Smart's telephone network and One Horizon's technologies."

About One Horizon Group, Inc.

One Horizon Group, Inc.'s business is to optimize communications over the Internet through its wholly owned subsidiary, Horizon Globex GmbH, Baar, which develops and markets one of the world's most bandwidth-efficient mobile Voice over Internet Protocol (VoIP) platforms for Smartphones, and also offers a range of other optimized data applications including messaging and mobile advertising. Horizon Globex GmbH is an ISO 9001 and ISO 20000-1 certified company. The Company has operations in Switzerland, the United Kingdom, China, India, Singapore, Hong Kong and Ireland. For more information on the Company, its products and services, please visit

About Smart Communications

Smart Communications, Inc. (Smart) is the Philippines' leading wireless services provider with 57.3 million subscribers on its GSM network as of end-June 2013. Smart has built a reputation for innovation, having introduced world-first wireless offerings such as Smart Money, Smart Load, Smart Padala, the Netphone, and Smart LTE. Smart also offers 3G and HSPA+ services, while its Smart Satellite Services provides communications to the global maritime industry. Smart Broadband, Inc., a wholly-owned subsidiary, offers a wireless broadband service, Smart Broadband, with 1.8 million subscribers as of end-June 2013.

Smart is a wholly owned subsidiary of the Philippines' leading telecommunications carrier, the Philippine Long Distance Telephone Company. For more information, visit

Safe Harbor Statement

This news release may contain "forward-looking" statements. These forward-looking statements are only predictions and are subject to certain risks, uncertainties and assumptions that could cause actual results to differ from those in the forward looking-statements. Potential risks and uncertainties include such factors as uncertainty of consumer demand for the Company's products, as well as additional risks and uncertainties that are identified and described in Company's SEC reports. Actual results may differ materially from the forward-looking statements in this press release. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company does not undertake, and it specifically disclaims, any obligation to update any forward-looking statements to reflect occurrences, developments, events or circumstances after the date of such statement.

MZ North America
Matthew Selinger
Tel: +1-949-298-4319
Email: Email Contact

Source: One Horizon Group, Inc.

More Press Releases

View Older Stories

Sep 16, 2014 07:30AM Sephora Enlists Epsilon For Permission-Based Email Marketing Services
Sep 16, 2014 07:30AM Milestone Scientific and Milestone China Form New Dermatological Joint Venture
Sep 16, 2014 07:30AM Marina Biotech Announces the Election of Donald A. Williams to Its Board of Directors
Sep 16, 2014 07:30AM Asian E-Discovery Growth Trends Highlighted in New FTI Consulting Study
Sep 16, 2014 07:30AM AP Lazer: New 2D Invention With Higher Profit Potential Than 3D Printer
Sep 16, 2014 07:30AM Enviro-Serv, Inc. Announces Second Dividend Distribution to All Non-Executive Common Shareholders
Sep 16, 2014 07:30AM Foster Wheeler Awarded EPCm Contract by Sasol for Electrical Expansion and Fuel Gas Superheater Project in Mozambique
Sep 16, 2014 07:30AM Goldman Small Cap Research Issues Research Report on Brazil Minerals, Inc.
Sep 16, 2014 07:30AM Venmar Ventilation inc. announces that it is expanding its Recall Program for certain models of air exchangers
Sep 16, 2014 07:30AM Deloitte Ranked No. 1 in Consulting in North America by Kennedy
Sep 16, 2014 07:30AM Skyhigh Networks Delivers Enhanced Cloud Security Capabilities with Palo Alto Networks Integration
Sep 16, 2014 07:30AM A.M. Best to Sponsor NRRA National Conference 2014
Sep 16, 2014 07:30AM Docker Secures $40M in Series C Funding to Drive the Future of Distributed Applications
Sep 16, 2014 07:30AM Ophthotech Announces Fovista® Phase 2b Independent Analysis Shows that Fovista® Anti-PDGF Therapy, Combined with Anti-VEGF Therapy, is Associated with a Reduction of Sub-retinal Fibrosis in Wet AMD
Sep 16, 2014 07:27AM Aberdeen Reports Shareholders' Equity of $0.39 Per Share and 2015 Second Quarter Financial Results
Sep 16, 2014 07:22AM The Melting Pot Toasts to Women and the Revival of Whiskey
Sep 16, 2014 07:22AM NCCPA: Five Ways Certified Physician Assistants Deliver Care When Your Health Can’t Wait
Sep 16, 2014 07:20AM Boston Therapeutics to Present Findings of BTI-320 as Therapy for Glycemic Control at 50th Annual Meeting of European Association for the Study of Diabetes
Sep 16, 2014 07:20AM Slyce Acquires Pounce: Single Swipe Payment Company
Sep 16, 2014 07:20AM WONDERBOLT: Clever DIY App by a Sailor/Engineer
Sep 16, 2014 07:20AM Primp and Blow, a Blow Dry Bar, Aims Higher With New Location
Sep 16, 2014 07:17AM VerInvest Corporation Launches Secure Accredited Investor Certification Service
Sep 16, 2014 07:16AM Launches the Now List; Offering Customers Additional Savings on Edgy Home Furnishings and Home Design Products
Sep 16, 2014 07:16AM Dabur chooses Ramco HCM (Human Capital Management)
Sep 16, 2014 07:15AM MKU Introduces 6th Generation Armour Technology – Sets New Benchmarks for Performance and Mission Capabilities of Armoured Helicopters
Sep 16, 2014 07:15AM Vanguard Natural Resources, LLC Signs Agreement to Acquire Natural Gas and Liquids Properties in the Piceance Basin in Colorado
Sep 16, 2014 07:15AM GOBankingRates Study Finds 11 Top Banks for Life's Biggest Financial Milestones
Sep 16, 2014 07:14AM Kristen McWilliams Provides CRM Support as New Anderson & Vreeland Appointment
Sep 16, 2014 07:14AM Sunrise Reputation Announces Availability of Online Reputation Management Services for Credit Card Companies
Sep 16, 2014 07:14AM Speedhut Introduces "Domed Window" Classic Styling for Modern Gauges
Sep 16, 2014 07:14AM 5 Common Mistakes in Fair Labor Standards Act That Should Be Avoided
Sep 16, 2014 07:13AM Debuts First Social Search Technology Platform and Community for Collectors
Sep 16, 2014 07:13AM Mattr Adds Values-Based Social Segmentation and Influence Marketing Features
Sep 16, 2014 07:13AM Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area
Sep 16, 2014 07:13AM Boinx Joins the 4K Revolution With FotoMagico 4.5
Sep 16, 2014 07:13AM Gaiam Launches Yoga Rising Series, Available Exclusively On iTunes
Sep 16, 2014 07:12AM Qorus Software to participate in the SharePoint Technology Conference 2014: Learn from the Experts
Sep 16, 2014 07:12AM Centura Tile, Canada's Premier Distributor of Floor and Wall Fashions, Discusses Three Issues to Address Before Selling a Home
Sep 16, 2014 07:11AM Bad Credit Auto Lender Shares 5 Best Road Trips in the US for 2014 in New Article
Sep 16, 2014 07:11AM Boopsie Launches Complete Package of App Usage Analytics for Libraries
Sep 16, 2014 07:11AM Projectmates V13.0 Raises the Bar for Construction Project Management Software
Sep 16, 2014 07:11AM Las Vegas' Award Winning Chapel of the Flowers Now Open Seven Days a Week
Sep 16, 2014 07:11AM Ramtha School Presents Capstone Event in Yelm Oct. 20-26
Sep 16, 2014 07:10AM The Android Alternative to Apple Pay
Sep 16, 2014 07:10AM 2014 Philadelphia Fiduciary Summit Gathers Local Employers and Plan Sponsors to Discuss 401(k) and 403(b) Best Practices
Sep 16, 2014 07:10AM New 'Learning Lounge' Offers Unique Take on DIY, Home Improvement
Sep 16, 2014 07:10AM Ultimus Celebrates 20 Years of Business Process Management Leadership
Sep 16, 2014 07:10AM SavingStar® Launches the SavingStar® American Express® Card Provided by First Bankcard®
Sep 16, 2014 07:09AM AxoGen, Inc. to Host Surgeon Education Event at American Society for Surgery of the Hand 2014 Annual Meeting
Sep 16, 2014 07:07AM Protein Sciences and Diamyd Medical Deepen Commitment to Develop New Treatment for Diabetes
View Older Stories